

# CITATION REPORT

List of articles citing

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)

DOI: 10.1007/s40259-019-00398-7  
BioDrugs, 2020, 34, 171-181.

**Source:** <https://exaly.com/paper-pdf/75239233/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
26	Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 27, 1432-1438	1.7	3
25	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , <b>2020</b> , 5, 15	2.1	26
24	A Clinical Review of Biosimilars Approved in Oncology. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 362-377	2.9	1
23	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , <b>2021</b> , 12, 2040620721989579	5.7	3
22	Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. <i>BioDrugs</i> , <b>2021</b> , 35, 459-468	7.9	2
21	Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. <i>Future Oncology</i> , <b>2021</b> , 17, 2529-2544	3.6	3
20	Monoclonal Antibodies for Cancer Treatment.		
19	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> ,	2	2
18	Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study. <i>Leukemia Research</i> , <b>2021</b> , 111, 106671	2.7	1
17	Introduction of Biosimilar Rituximab: A Hospital Perspective. <i>HemaSphere</i> , <b>2021</b> , 5, e515	0.3	4
16	Targeting CD20: teaching an old dog new tricks. <i>Hematology American Society of Hematology Education Program</i> , <b>2019</b> , 2019, 273-278	3.1	4
15	The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma. <i>Korean Journal of Internal Medicine</i> , <b>2021</b> , 36, 1459-1470	2.5	
14	Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study.. <i>Future Oncology</i> , <b>2022</b> ,	3.6	
13	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.. <i>JAMA Oncology</i> , <b>2022</b> ,	13.4	0
12	An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.. <i>Ophthalmology and Therapy</i> , <b>2022</b> ,	5	1
11	A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.. <i>Clinical Drug Investigation</i> , <b>2022</b> , 42, 285	3.2	0
10	A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. <i>International Journal of Clinical Pharmacy</i> , <b>2021</b> , 44, 366	2.3	

9 Biosimilar Monoclonal Antibodies in Latin America.

8 Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. *Journal of Oncology Pharmacy Practice*, 107815522211104 1.7

7 Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review. ○

6 Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. **2022**, 155, 335 ○

5 Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis. ○

4 Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. ○

3 Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis. **2023**, 37, 205-218 ○

2 Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System. ○

1 Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States. 1-9 ○